Spontaneous Epidural Hematomas due to Cerebral Venous Thrombosis in a Patient with Immune Thrombocytopenic Purpura

Ntantos, Dimitrios; Karantali, Eleni; Prevezianou, Angeliki; Angelopoulos, Petros; Bostantjopoulou, Sevasti

doi:10.1016/j.jstrokecerebrovasdis.2020.105244

Cited by 7 publications

(15 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Compared to our findings, we discovered that CVT related to TPO-RAs can impact both men and women. Intracranial hemorrhage with additional intraventricular hemorrhage has a worse prognosis than the patient without intracerebral hemorrhage, compatible with the previously reported case [ 8 ]. Unfractionated heparin and low molecular weight heparin were administered in the acute phase and subsequently switched to oral anticoagulants.…”

Section: Discussionsupporting

confidence: 90%

Cerebral venous sinus thrombosis in immune thrombocytopenia patients treated with thrombopoietin receptor agonist: Case reports and literature review

Teekaput

Nadsasarn

Tanprawate

et al. 2022

Annals of Medicine &Amp; Surgery

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 90%

Cerebral venous sinus thrombosis in immune thrombocytopenia patients treated with thrombopoietin receptor agonist: Case reports and literature review

Teekaput

Nadsasarn

Tanprawate

et al. 2022

Annals of Medicine &Amp; Surgery

View full text Add to dashboard Cite

“…Immune thrombocytopenic purpura (ITP) is an acquired autoimmune hematological disease. It is characterized by antibody-mediated platelet destruction causing thrombocytopenia [1,2].…”

Section: Introductionmentioning

confidence: 99%

“…e clinical manifestations are widely diversi ed, and some patients can be completely asymptomatic or express some minor bleeding symptoms including purpura, petechiae, epistaxis, and hemorrhage tendency. On the other hand, it may present with lethal bleeding such as intracranial hemorrhage, especially during severe thrombocytopenia [1,2].…”

Section: Introductionmentioning

confidence: 99%

“…Asymptomatic patients may require only close observation. However, the main agents used in the treatment of ITP include corticosteroids, intravenous immunoglobulin (IVIG), thrombopoietin receptor agonist, and splenectomy [1].…”

Section: Introductionmentioning

confidence: 99%

“…Cerebral venous thrombosis (CVT) is a relatively uncommon but serious condition that occurs mostly in the presence of a hypercoagulable state, which has several causes including pregnancy, inherited and acquired thrombophilia, infections, and malignancies [1].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Primary Cerebral Venous Thrombosis in a Patient with Immune Thrombocytopenic Purpura

Farfouti

Masri

Ghabally

et al. 2022

Case Reports in Neurological Medicine

View full text Add to dashboard Cite

Introduction. Immune thrombocytopenic purpura is an autoimmune hematological disorder characterized by low platelet level due to its destruction through autoimmune antibodies. Cerebral venous thrombosis is a serious condition defined by a thrombosis in the cerebral venous sinuses that occurs mostly in the presence of a hypercoagulable state. Hemorrhage and thrombosis are processes with a paradoxical etiology; thus, the association between these two conditions seems to be extremely rare. Case Presentation. We herein report a case of a 19-year-old female with a chief compliant of generalized tonic-clonic episode, severe headache, and blurred vision. Physical examination was significant for a bilateral Babinski’s sign and severe bilateral papilledema. Laboratory workup, computed tomography, and magnetic resonance imaging were normal except for severe thrombocytopenia. Magnetic resonance venography was diagnostic for cerebral venous thrombosis. Her past medical history was significant for immune thrombocytopenic purpura that was treated with prednisolone 40 mg per day which posed a therapeutic challenge. High-dose prednisolone and platelet transfusion were initiated; enoxaparin was administrated and switched to warfarin after stabilization of platelet count. The patient was neurologically intact after 14 days of appropriate treatment and was on follow-up. Many hypotheses were suggested to explain the unexpected thrombotic events in a patient with immune thrombocytopenic purpura which were related to the disease etiology or treatment, taking into account common risk factors (such as age, obesity, smoking, hypertension, diabetes mellitus, dyslipidemia, splenectomy, and oral contraceptive agents). Conclusion. The association between immune thrombocytopenic purpura (which is a major risk factor for bleeding) and cerebral venous thrombosis ( which is caused by a thromboembolic event )has carried a major challenge to the management plan. We believe that immune thrombocytopenic purpura and its treatment methods should be taken into consideration as risk factors for thromboembolic phenomenon.

show abstract

Cerebral venous sinus thrombosis in patient of immune thrombocytopenic purpura managed with mechanical thrombectomy: An anecdotal endovascular experience from lower middle income country

Ghimire,

Shrestha,

Shrestha

et al. 2024

Clinical Case Reports

View full text Add to dashboard Cite

show abstract

Spontaneous Epidural Hematomas due to Cerebral Venous Thrombosis in a Patient with Immune Thrombocytopenic Purpura

Cited by 7 publications

References 15 publications

Cerebral venous sinus thrombosis in immune thrombocytopenia patients treated with thrombopoietin receptor agonist: Case reports and literature review

Cerebral venous sinus thrombosis in immune thrombocytopenia patients treated with thrombopoietin receptor agonist: Case reports and literature review

Primary Cerebral Venous Thrombosis in a Patient with Immune Thrombocytopenic Purpura

Cerebral venous sinus thrombosis in patient of immune thrombocytopenic purpura managed with mechanical thrombectomy: An anecdotal endovascular experience from lower middle income country

Contact Info

Product

Resources

About